Prostate cancer is a leading cause of cancer-related morbidity and mortality, accounting for 288 300 new cases and 34 700 deaths each year.1 Few consistent modifiable risk factors for prostate cancer have been identified, limiting the scope for primary prevention.2 Use of prostate-specific antigen (PSA) screening is widespread in the US but controversial. This evidence concerns the gene KLK3 and prostate cancer.